Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

The total market value of ALL pharma and biotech companies is $4.6 trillion.

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

Licensing remains a dominant model. The value of the licensing-out deals signed by Chinese biotech firms in the first half of ...

The U.S. has ceded its leadership in critical industries before. It must not do so with China and biotech now, writes the ...